PortalPublikationenEvaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for The...

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases

Standard

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases. / Fernández, René; Eppard, Elisabeth; Lehnert, Wencke; Jiménez-Franco, Luis David; Soza-Ried, Cristian; Ceballos, Matías; Ribbeck, Jessica; Kluge, Andreas; Rösch, Frank; Meckel, Marian; Zhernosekov, Konstantin; Kramer, Vasko; Amaral, Horacio.

in: J NUCL MED, Jahrgang 62, Nr. 8, 01.08.2021, S. 1126-1132.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fernández, R, Eppard, E, Lehnert, W, Jiménez-Franco, LD, Soza-Ried, C, Ceballos, M, Ribbeck, J, Kluge, A, Rösch, F, Meckel, M, Zhernosekov, K, Kramer, V & Amaral, H 2021, 'Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases', J NUCL MED, Jg. 62, Nr. 8, S. 1126-1132. https://doi.org/10.2967/jnumed.120.255851

APA

Fernández, R., Eppard, E., Lehnert, W., Jiménez-Franco, L. D., Soza-Ried, C., Ceballos, M., Ribbeck, J., Kluge, A., Rösch, F., Meckel, M., Zhernosekov, K., Kramer, V., & Amaral, H. (2021). Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases. J NUCL MED, 62(8), 1126-1132. https://doi.org/10.2967/jnumed.120.255851

Vancouver

Fernández R, Eppard E, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Ceballos M et al. Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases. J NUCL MED. 2021 Aug 1;62(8):1126-1132. https://doi.org/10.2967/jnumed.120.255851

Bibtex

@article{194d3b359abf49ecb8f2a0255bfe6f17,
title = "Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases",
abstract = "Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods: Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional whole-body SPECT/CT imaging and venous blood sampling over 7 d. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Results: 177Lu-DOTA-ZOL showed fast uptake and high retention in bone lesions and fast clearance from the bloodstream in all patients. The average retention in tumor lesions was 0.02% injected activity per gram at 6 h after injection and approximately 0.01% at 170 h after injection. In this cohort, the average absorbed doses in bone tumor lesions, kidneys, red bone marrow, and bone surfaces were 4.21, 0.17, 0.36, and 1.19 Gy/GBq, respectively. The red marrow was found to be the dose-limiting organ for all patients. A median maximum tolerated injected activity of 6.0 GBq may exceed the defined threshold of 2 Gy for the red bone marrow in individual patients (4/8). Conclusion: 177Lu-DOTA-ZOL is safe and has a favorable therapeutic index compared with other radiopharmaceuticals used in the treatment of osteoblastic bone metastases. Personalized dosimetry, however, should be considered to avoid severe hematotoxicity for individual patients.",
keywords = "Heterocyclic Compounds, 1-Ring, Humans, Male, Middle Aged, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Castration-Resistant, Radiometry",
author = "Ren{\'e} Fern{\'a}ndez and Elisabeth Eppard and Wencke Lehnert and Jim{\'e}nez-Franco, {Luis David} and Cristian Soza-Ried and Mat{\'i}as Ceballos and Jessica Ribbeck and Andreas Kluge and Frank R{\"o}sch and Marian Meckel and Konstantin Zhernosekov and Vasko Kramer and Horacio Amaral",
note = "{\textcopyright} 2021 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2021",
month = aug,
day = "1",
doi = "10.2967/jnumed.120.255851",
language = "English",
volume = "62",
pages = "1126--1132",
journal = "J NUCL MED",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases

AU - Fernández, René

AU - Eppard, Elisabeth

AU - Lehnert, Wencke

AU - Jiménez-Franco, Luis David

AU - Soza-Ried, Cristian

AU - Ceballos, Matías

AU - Ribbeck, Jessica

AU - Kluge, Andreas

AU - Rösch, Frank

AU - Meckel, Marian

AU - Zhernosekov, Konstantin

AU - Kramer, Vasko

AU - Amaral, Horacio

N1 - © 2021 by the Society of Nuclear Medicine and Molecular Imaging.

PY - 2021/8/1

Y1 - 2021/8/1

N2 - Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods: Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional whole-body SPECT/CT imaging and venous blood sampling over 7 d. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Results: 177Lu-DOTA-ZOL showed fast uptake and high retention in bone lesions and fast clearance from the bloodstream in all patients. The average retention in tumor lesions was 0.02% injected activity per gram at 6 h after injection and approximately 0.01% at 170 h after injection. In this cohort, the average absorbed doses in bone tumor lesions, kidneys, red bone marrow, and bone surfaces were 4.21, 0.17, 0.36, and 1.19 Gy/GBq, respectively. The red marrow was found to be the dose-limiting organ for all patients. A median maximum tolerated injected activity of 6.0 GBq may exceed the defined threshold of 2 Gy for the red bone marrow in individual patients (4/8). Conclusion: 177Lu-DOTA-ZOL is safe and has a favorable therapeutic index compared with other radiopharmaceuticals used in the treatment of osteoblastic bone metastases. Personalized dosimetry, however, should be considered to avoid severe hematotoxicity for individual patients.

AB - Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods: Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional whole-body SPECT/CT imaging and venous blood sampling over 7 d. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Results: 177Lu-DOTA-ZOL showed fast uptake and high retention in bone lesions and fast clearance from the bloodstream in all patients. The average retention in tumor lesions was 0.02% injected activity per gram at 6 h after injection and approximately 0.01% at 170 h after injection. In this cohort, the average absorbed doses in bone tumor lesions, kidneys, red bone marrow, and bone surfaces were 4.21, 0.17, 0.36, and 1.19 Gy/GBq, respectively. The red marrow was found to be the dose-limiting organ for all patients. A median maximum tolerated injected activity of 6.0 GBq may exceed the defined threshold of 2 Gy for the red bone marrow in individual patients (4/8). Conclusion: 177Lu-DOTA-ZOL is safe and has a favorable therapeutic index compared with other radiopharmaceuticals used in the treatment of osteoblastic bone metastases. Personalized dosimetry, however, should be considered to avoid severe hematotoxicity for individual patients.

KW - Heterocyclic Compounds, 1-Ring

KW - Humans

KW - Male

KW - Middle Aged

KW - Positron Emission Tomography Computed Tomography

KW - Prostatic Neoplasms, Castration-Resistant

KW - Radiometry

U2 - 10.2967/jnumed.120.255851

DO - 10.2967/jnumed.120.255851

M3 - SCORING: Journal article

C2 - 33419945

VL - 62

SP - 1126

EP - 1132

JO - J NUCL MED

JF - J NUCL MED

SN - 0161-5505

IS - 8

ER -